Baidu
map

J Clin Oncol:ARIEL3试验的研究后探索分析

2020-08-26 MedSci原创 MedSci原创

3期ARIEL3研究对比了rucaparib(鲁卡帕利)和安慰剂维持治疗复发性卵巢癌的临床疗效,结果显示与安慰剂相比,鲁卡帕利具有明显的临床效益。Oza等对该试验进行了一次事后探索分析,以评估经过质量

3期ARIEL3研究对比了rucaparib(鲁卡帕利)和安慰剂维持治疗复发性卵巢癌的临床疗效,结果显示与安慰剂相比,鲁卡帕利具有明显的临床效益。Oza等对该试验进行了一次事后探索分析,以评估经过质量校正的无进展生存期(QA-PFS)和无症状或毒性时间(Q-TWiST)。

ARIEL3的研究对象是铂敏感的、复发性卵巢癌患者,随机分至鲁卡帕利组(600 mg 2/日)或安慰剂组。

截止2017年4月15日,在意向治疗人群(ITT)中,鲁卡帕利组(375人)的平均QA-PFS明显长于安慰剂组(189人)(相差6.28个月);此外,在BRCA突变队列(130人 vs 66人)、同源重组修复缺陷(HRD)队列(236 vs 118)和BRCA野生型或杂合缺失(LOH)低的患者队列(107 vs 54)中,鲁卡帕利组的平均QA-PFS也均明显长于安慰剂组(分别相差9.37个月、7.93个月和2.71个月)。

采用≥3级TEAE定义的TOX,在ITT人群、BRCA突变队列、HRD队列和BRCA野生型/LOH低患者队列中鲁卡帕利组和安慰剂组的平均Q-TWiST差分别是6.88个月、9.73个月、8.11个月和3.35个月。

总结:鲁卡帕利和安慰剂之间QA-PFS和Q-TWiST的明显差异证明了鲁卡帕利在所有预定的队列中的效益都明显优于安慰剂。

相关研究:

Lancet oncol:ARIEL3试验:Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析

晚期卵巢癌:Rubraca的III期ARIEL3研究的最新数据

Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗

Lancet:Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗

FDA批准Clovis PARP抑制剂rucaparib

原始出处:

Amit M. Oza,et al. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. Journal of Clinical Oncology. August 24, 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2021-06-01 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2021-04-30 MedSciZeng

    #J Clin Oncol#点击查看更多该期刊内容

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-29 qinqiyun

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-28 ms3000000449926787

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    相关资讯请继续分享,谢谢

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    很好很详细,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-26 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1865897, encodeId=a161186589e3d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 01 02:04:37 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961842, encodeId=f44896184254, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:16:17 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880518, encodeId=c2168805185a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Sat Aug 29 00:03:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814693, encodeId=6d2d8146936d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Aug 28 11:54:11 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517119, encodeId=1d90151e119da, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri Aug 28 06:04:37 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814016, encodeId=238981401631, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:45 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813954, encodeId=c14381395432, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:14:02 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813895, encodeId=28f981389541, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:50 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038099, encodeId=fbf91038099c9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Aug 26 18:04:37 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813447, encodeId=839781344e3a, content=<a href='/topic/show?id=dba615e3883' target=_blank style='color:#2F92EE;'>#rucaparib#</a><a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>铂敏感性复发性<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,这是非常惊人的数据了。各种亚组分析均能获益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=306, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15738, encryptionId=dba615e3883, topicName=rucaparib), TopicDto(id=79040, encryptionId=4012e904074, topicName=维持治疗), TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Aug 26 16:02:43 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-26 lovetcm

    #rucaparib##维持治疗#铂敏感性复发性#卵巢癌#,这是非常惊人的数据了。各种亚组分析均能获益。

    0

相关资讯

FDA批准Clovis PARP抑制剂rucaparib

今天FDA批准了Clovis的PARP抑制剂rucaparib(商品名Rubraca)作为三线以后药物用于BRCA变异晚期卵巢癌。同时FDA还批准了FoundationFocus 的伴随诊断试剂CDxBRCA。Rucaparib在两个二期临床共106位病人中显示54%的应答率,PFS为9.2个月。PDUFA原定为2017年2月23日,所以提前这么长时间批准有点令人意外。今天Clovis股票上扬

Lancet:Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗。

Rucaparib,PARP抑制剂,对携带BRCA突变或者大片段基因杂合缺失的复发性卵巢癌具有抗癌作用。在本试验中,研究人员评估Rucaparib用于经二线治疗或后以顺铂为基础的化疗获得完全或部分缓解的高级别、复发性、铂类药物敏感性卵巢癌患者维持治疗的效果。

Lancet oncol:ARIEL3试验:Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析

在ARIEL3试验(评估PARP抑制剂rucaparib用于复发性卵巢癌)中,rucaparib维持治疗可较安慰剂显著提高患者的无进展存活期。现Ledermann等人将预先确定的、研究者评估的、探索性

FDA认定rucaparib作为前列腺癌突破性疗法资格

Clovis Oncology公司10月2日宣布,Rubraca (rucaparib)用于单药治疗既往接受过抗雄激素受体疗法以及紫杉烷类化疗的BRCA1/2+成人转移性去势抵抗前列腺癌(mCRPC)已被FDA授予突破性疗法资格。rucaparib之前也被FDA授予过单药治疗特定晚期卵巢癌患者的突破性疗法资格,并且在2016年12月19日被FDA批准用于单药治疗既往接受过两种以上化疗的BRCA突变

Baidu
map
Baidu
map
Baidu
map